Facility and Equipment maintenance are deficient in their ability to support cGMP production activities.
Inspection Record
Ajinomoto Althea, Inc. — FDA 483 Findings
Inspectors Christopher R. CzajkaThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Quality oversight of validation activities is inadequate.
About this record
Extracted automatically from the document US FDA published on 2023-04-25. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
